KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Treasury Shares (2021 - 2025)

Recursion Pharmaceuticals' Treasury Shares history spans 5 years, with the latest figure at $27.5 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 0.68% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, up 0.68%, while the annual FY2025 figure was $27.5 million, 0.68% up from the prior year.
  • Treasury Shares reached $27.5 million in Q4 2025 per RXRX's latest filing, down from $30.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $30.6 million in Q3 2025 to a low of $76762.0 in Q2 2021.
  • Average Treasury Shares over 5 years is $14.1 million, with a median of $15.6 million recorded in 2024.
  • Peak YoY movement for Treasury Shares: surged 9055.72% in 2022, then increased 0.68% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $478136.0 in 2021, then surged by 1341.96% to $6.9 million in 2022, then surged by 120.81% to $15.2 million in 2023, then skyrocketed by 79.35% to $27.3 million in 2024, then rose by 0.68% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Treasury Shares are $27.5 million (Q4 2025), $30.6 million (Q3 2025), and $21.7 million (Q2 2025).